Navigation Links
Scientists Identify New Possible 'biomarker' for Pancreatic Cancer

University of Cincinnati researchers have identified a specific cell receptor, which they say is a potential biological target for pancreatic cancer.

Led by Dr. Andrew Lowy and Dr. Susan Waltz, the study found that the RON receptor tyrosine kinase was "over-expressed" in pancreatic cancer cells, suggesting that the receptor may also contribute to the disease's development.

The researchers say that their findings, published in the journal Cancer Research, may help scientists better understand and treat the disease that kills more than 33,000 people each year.

Published in the journal Cancer Research, this is the first study to establish the link between the RON receptor and pancreatic cancer. The report also tells that receptor tyrosine kinases are proteins on the cell surface used to activate specific body functions like cell growth and migration.

"A normal pancreas has very low levels of RON, but our study showed that as tumours progress, so does the level of RON expression in the pancreas cells -- and those over expressed levels were maintained in 'metastases,' the areas that the tumours spread to," explains Waltz, Associate Professor and Director of the Oncology Research Program, Surgery Department, Cincinnati University.

During the study, the researchers noted that the RON receptor was active in 93 per cent of pancreatic intraepithelial neoplasia, an early form of pancreatic duct cancer. They also observed that the receptor was present in 79 per cent of primary pancreatic cancers, and 83 per cent of metastatic cancers.

Waltz believes that the RON receptor's signalling pathways may be a key factor contributing to pancreatic cancer progression, and that it may give drug developers a new target for RON directed therapies that are more effective in treating the deadly disease.

"When cells became invasive, we saw higher levels of RON expression that correlated with the aggressive nature of this disease and cancer metastasis. Clearly, this signaling pathway is associated with pancreatic cancer and merits further investigation," Waltz said.

During the study, the researchers used the protein HGFL to activate the RON receptor.

They observed that though stimulating the RON receptor had no effect on pancreatic cell growth, blocking it with targeted antibodies killed more cancer cells than did the standard treatment drug gemcitabine alone.

"Our findings suggest that combining antibodies that block the RON receptor and the standard chemotherapy drugs might stop progression of pancreatic cancer more effectively. RON could be a promising molecular target for future cancer drug development," says Waltz.

However, the researchers, who had reported in December last year the association between the RON receptor and breast cancer, say that further studies is needed before blockers for the RON receptors may be used for human testing.


'"/>




Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. Scientists found ancient Human Germ Killer
3. Scientists locate key hormone involved in appetite control
4. Scientists open the book of life
5. Scientists review SARS
6. Scientists crack dengue fever puzzle
7. Scientists push to lower hidden sodium in food
8. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
9. Scientists have found effective brain regions for deep brain stimulation for Parkinson’s
10. Scientists reveal the secrets of sarcasm
11. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... Everybody has ... it while others prefer to read it, and some people don't like it at ... pornography. Here's what they found: , Erotic literature can give readers a taste of ...
(Date:6/23/2017)... ... ... 21 Middle East and South Asia Leaders Selected as Eisenhower Fellows ... civil society in 11 countries across the Middle East and South Asia to embark ... of knowledge and ideas with the leading minds in their fields. , For ...
(Date:6/23/2017)... , ... June 23, 2017 , ... Ulster University, Magee ... 2017 from 9 am to 3 pm to present to graduate students exciting new ... is an original curriculum project led by The Health Improvement Service of the Western ...
(Date:6/23/2017)... Woodlands, TX (PRWEB) , ... June 23, 2017 ... ... families and business owners in the Houston area with access to asset protection ... for a regional charity event aimed at improving the lives of children with ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... grant from the American Heart Association (AHA) to launch a Rheumatic Heart Disease ... the prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... URBANDALE, Iowa , June 6, 2017  Diplomat Specialty Infusion ... a sterile compounding environment to its Iowa ... Urbandale now features an ISO 7 cleanroom—the ... a controlled environment with a low level of pollutants. ... serve more IV nutrition consumers and better serve our ...
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings ... Veterinarian Recommended Solutions (VRS), and KD Pharma Group have ... Nutriceutical Holdings by KD Pharma Group. KD Pharma Group ... the option to acquire the entire company. ... KD. They are committed to growing the NH companies ...
(Date:5/26/2017)... , May 26, 2017  Endo International plc (NASDAQ: ... President and CEO, will represent the Company in a fireside ... Conference on Tuesday, June 13, 2017 at 10:40 a.m. PT ... Terranea Resort in Rancho Palos Verdes, CA. ... the event will be available on the Company,s website at ...
Breaking Medicine Technology: